# US 12,214,031 B2 · Mannheimia haemolytica vector

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,214,031 B2
- Document ID: US12214031B2
- Status: Granted
- Kind: B2
- Application number: 18/310,821
- Filed: 2023-05-02
- Published: 2023-10-19
- Granted: 2025-02-04
- Earliest claimed: 2020-03-03
- Assignees: The United States of America as represented by the Secretary of Agriculture
- Applicants: The United States of America, as represented by The Secretary of Agriculture
- Inventors: Robert E. Briggs; Fred M. Tatum
- Web page: https://patentgrep.com/patent/US12214031B2

## CPC

- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- A61K 39/0241: {Mollicutes, e.g. Mycoplasma, Erysipelothrix}
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61P 31/04: Antibacterial agents
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/543: {intranasal}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to modified Mannheimia haemolytica (M. haemolytica) lktCA gene cluster cassettes, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions. Also described herein are Mycoplasma bovis (M. bovis) protective antigens, compositions comprising such antigens, methods of using such antigens and compositions, and kits comprising such antigens and compositions. Also described herein are modified M. haemolytica lktCA gene cluster cassettes engineered to express M. bovis protective antigens, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions.

## Claims

### Claim 1

A cassette comprising a modified Mannheimia haemolytica lktCA gene cluster, wherein the modified M. haemolytica lktCA gene cluster comprises two polynucleotides encoding leukotoxin neutralizing epitopes, a first polynucleotide encoding the native leukotoxin neutralizing epitope, and a second polynucleotide encoding an additional leukotoxin neutralizing epitope inserted immediately downstream of the native leukotoxin A start codon.

### Claim 2 (depends on 1)

A composition comprising the cassette of claim 1, wherein the composition is a polynucleotide, a plasmid, an expression vector, a host cell, a vaccine, or an immunogenic composition.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the composition is a replacement plasmid, an attenuated M. haemolytica strain A1 bacterium, or an attenuated M. haemolytica strain A6 bacterium.

### Claim 4 (depends on 1)

The cassette of claim 1, further comprising at least one polynucleotide encoding a heterologous antigen.

### Claim 5 (depends on 4)

The cassette of claim 4, wherein the at least one polynucleotide encoding a heterologous antigen is inserted upstream of the polynucleotide encoding the added leukotoxin neutralizing epitope.

### Claim 6 (depends on 4)

A composition comprising the cassette of claim 4, wherein the composition is a polynucleotide, a plasmid, an expression vector, a host cell, a vaccine, or an immunogenic composition.

### Claim 7 (depends on 4)

The cassette of claim 4, wherein the at least one polynucleotide encoding a heterologous antigen is at least one M. bovis antigen.

### Claim 8 (depends on 1)

A kit comprising the cassette of claim 1.

### Claim 9 (depends on 4)

A kit comprising the cassette of claim 4.

### Claim 10 (depends on 6)

A kit comprising the composition of claim 6.